Publications by authors named "Deesha D Desai"
Premature hair graying (PHG) is the early loss of natural hair color, influenced by genetic, biological, and environmental factors. This review discusses the significant psychological impacts of PHG and explores its underlying mechanisms, related health conditions, and available treatments. The review examines the roles of genetics, oxidative stress, and lifestyle factors such as smoking and diet in premature graying.
View Article and Find Full Text PDFArticle Synopsis
- Performance-enhancing drugs like testosterone are commonly used by athletes and young males to boost muscle growth and strength, but they come with serious health risks such as liver damage, gynecomastia, and hair loss.
- The popularity of testosterone for improving performance and appearance is increasing, yet there are no clear guidelines for safe dosages.
- This study focuses on how testosterone affects hair health in males and seeks to create guidelines for safe and responsible use, emphasizing the importance of informed healthcare decisions.
LDOM has enhanced treatment options for female AGA, yet its combined efficacy with therapies such as spironolactone, finasteride, or dutasteride remains inadequately explored. This study aims to compare the efficacy and safety of LDOM in combination with spironolactone versus LDOM with finasteride or dutasteride in women with AGA. Our analysis revealed that both combination therapies produced similar improvements in hair growth and had comparable safety profiles.
View Article and Find Full Text PDFArticle Synopsis
- Androgenetic alopecia (AGA) affects both the hair and the psychological well-being of patients, with few treatment options available in the past.
- The introduction of low-dose oral minoxidil (LDOM) has changed the game for managing AGA.
- A study found that LDOM works effectively and safely for both patients with AGA alone and those with AGA alongside telogen effluvium, suggesting it can enhance patient outcomes and quality of life.
Alopecia areata (AA) has long been considered a challenging clinical condition, with dermatologists traditionally employing corticosteroids and immunosuppressants in search of effective solutions. The introduction of Janus kinase inhibitors (JAKi), specifically the Food and Drug Administration (FDA) approval of baricitinib, marked a significant breakthrough in the treatment of AA. Clinical trials have shown promising results with baricitinib, and reports of relapse after initial success are scarce.
View Article and Find Full Text PDFArticle Synopsis
- - Keratosis pilaris atrophicans faciei (KPAF) and frontal fibrosing alopecia (FFA) are similar skin conditions that make diagnosis tricky for dermatologists, often leading to overlapping treatment methods.
- - Genetic testing holds promise for more precise diagnoses and personalized treatment plans for these conditions, but it hasn't been widely applied yet.
- - The case study of a 36-year-old male shows that despite negative genetic testing results, exploring genetic factors can still improve diagnosis and treatment efficacy for similar dermatological issues.
Article Synopsis
- The use of GLP-1 agonists for treating type 2 diabetes and obesity has led to discussions about their effects on hair health.
- While some sources claim these medications may cause issues like hair loss, others suggest they could improve hair growth due to better insulin sensitivity and blood flow to the scalp.
- There is currently limited clinical evidence on the link between GLP-1 agonists and hair loss, highlighting the importance of monitoring patients and working together to understand these effects better.
Article Synopsis
- The study focuses on how SARS-CoV-2 affects the quality of life related to the nose and sinuses, sense of smell, and cognitive abilities at various stages of infection.
- *Olfactory dysfunction is common in COVID-19 patients, and while the sense of smell may improve over time, cognitive issues, particularly in processing speed, persist even after recovery.
- *The results indicate that recovered patients scored lower in smell tests compared to those actively infected or healthy controls, highlighting that olfactory and cognitive impacts from the virus can vary significantly.